NCT03682263 (SED) is a NA clinical trial of Full Service in Mental Impairment, sponsored by Westat.

Who is sponsoring NCT03682263?

NCT03682263 is sponsored by Westat.

What drugs are being tested in NCT03682263?

Interventions in NCT03682263: Full Service, Basic Service.

What condition does NCT03682263 study?

NCT03682263 studies Mental Impairment.

Is NCT03682263 still recruiting?

NCT03682263 is currently completed. Last updated 14 April 2022.

Last reviewed 2022-04-14 · How we verify

NCT03682263: SED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Supported Employment Demonstration

Completed NA Last updated 14 April 2022

What this trial tests

NA trial testing Full Service in Mental Impairment in 3,000 participants. Completed in 31 March 2022.

Timeline

2 December 2017

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Westat
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	3,000
Start date	2 December 2017
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	52 locations across United States

Drugs / interventions tested

Full Service
Basic Service

Conditions studied

Mental Impairment — all drugs for Mental Impairment →

Sponsor

Westat — full company profile →

Who can join

Adults 18 to 49, any sex, with Mental Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether offering an evidence-based package of employment supports integrated with mental health services has a positive impact on employment and clinical recovery, and delays or diminishes the need for disability benefits.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Enrollment in the Supported Employment Demonstration: An Employment Intervention for Denied Disability Benefits Applicants with a Mental Impairment.
Taylor JA, Salkever DS, Frey WD, Riley J, et al · · 2022 · cited 1× · PMID 34405312 · DOI 10.1007/s10488-021-01159-x

Verify or expand the search:

Other Westat trials

Trials by the same sponsor.

NCT06738407 — Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections · Phase 4 · recruiting
NCT06444360 — Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults · NA · recruiting
NCT05255445 — Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients · completed
NCT04118738 — International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy · completed
NCT03543722 — Independence Project · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03682263 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Westat
Last refreshed: 14 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing